Margaret (Mandy) MacLean MBE FRSE is an expert in pulmonary pharmacology. She is renowned for her work on the role of sex effects and serotonin in metabolising oestrogen, also for identifying target enzymes for the treatment of pulmonary arterial hypertension. MacLean is currently a Professor of Pulmonary Pharmacology in the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde Glasgow.[1]
Margaret MacLean | |
|---|---|
| Mandy MacLean | |
| Alma mater | PhD in Pharmacology from the University of Edinburgh - 1985 |
| Awards | MBE - 2010
Fellow of The Royal Society of Edinburgh (FRSE) - 2013 British Pharmacological Society AstraZeneca Prize for Women in Pharmacology - 2013 |
| Scientific career | |
| Fields | Pulmonary pharmacology |
| Institutions | University of Strathclyde, Glasgow |
MacLean was awarded the MBE in the 2010 Queen’s New Year Honours list.[2] In 2013, MacLean was elected Fellow of The Royal Society of Edinburgh (FRSE) and received the British Pharmacological Society AstraZeneca Prize for Women in Pharmacology.[1] In 2018, she was made a Fellow of the Academy of Medical Sciences (FMedSci)[3] and was appointed Scottish Champion for the Academy of Medical Sciences[1] for her efforts in science communication.
References
edit- ^ a b c "Mandy MacLean". University of Strathclyde. Retrieved 5 June 2019.
- ^ "The complete New Year Honours lists, 2010". BBC. 31 December 2009. Retrieved 5 June 2019.
- ^ "Professor Margaret (Mandy) MacLean". The Academy of Medical Sciences. Retrieved 5 June 2019.
   | This Scottish biographical article related to medicine is a stub. You can help Wikipedia by expanding it. |